These facts come from FDA’s list of registered outsourcing facilities, updated November 17, 2026, and from the inspection report FDA posted with it.1 FDA’s warning letters about GLP-1 drugs name this company 2 times; they are listed below.
What does FDA’s record show, in brief?
| Facility | ProRx LLC |
| Location | Exton, Pennsylvania |
| Type | 503B outsourcing facility |
| Registered since | April 27, 2022 |
| Latest registration | February 20, 2026 |
| Last FDA inspection | November 10, 2026 |
| Inspection dates | — |
| Form 483 | Issued |
| FDA action after the inspection | Open |
| Compounds sterile drugs from bulk | Yes |
| FDA warning letters on GLP-1 drugs | 2 |
Has this facility recalled any drugs?
FDA’s enforcement reports list 14 recalled products from this facility, from August 22, 2024 to October 15, 2025: 14 in Class II. 14 of them name a GLP-1 drug. Class I is the most serious: FDA uses it when the product could cause serious harm.3
| Started | Class | Product | Reason |
|---|---|---|---|
| 2025-10-15 | II | Semaglutide Injection | Lack of Assurance of Sterility |
| 2025-10-15 | II | Semaglutide Injection | Lack of Assurance of Sterility |
| 2025-10-15 | II | Semaglutide Injection | Lack of Assurance of Sterility |
| 2025-10-15 | II | Semaglutide Injection | Lack of Assurance of Sterility |
| 2025-10-15 | II | Tirzepatide Injection | Lack of Assurance of Sterility |
| 2025-10-15 | II | Semaglutide Injection | Lack of Assurance of Sterility |
| 2025-10-15 | II | Semaglutide Injection | Lack of Assurance of Sterility |
| 2024-08-22 | II | Tirzepatide 2 mL (10 mg/mL) and 20 mg/mL | Lack of Assurance of Sterility |
The table shows 8 of the 14 recalls, those naming a GLP-1 drug first; the rest are in FDA’s enforcement reports.
Which FDA warning letters name this company?
Is the pharmacy behind my prescription on FDA’s list?
Type a pharmacy name or city. The search runs over all 100 facilities on FDA’s list; a 503A pharmacy that compounds for individual prescriptions is licensed by its state and is not on this list.
Where are the registered outsourcing facilities?
6 of the 100 facilities on FDA’s list are in Pennsylvania. The chart counts them by state; choose a view to see which ones FDA has inspected.
Which other facilities are in the same state?
What does it mean that a pharmacy is a 503B outsourcing facility?
An outsourcing facility is a compounder that has chosen to register with FDA under section 503B of the Federal Food, Drug, and Cosmetic Act. It must re-register every year between October 1 and December 31 and pay an annual fee; a facility that does not is removed from FDA’s list on January 1.1 Once registered, it joins the list of facilities FDA plans to inspect on a risk-based schedule.1
A Form FDA 483 lists what investigators observed during an inspection. FDA states that a 483 is issued when investigators see significant objectionable conditions, and that it is not a final agency determination that the law was broken.1 Registration is not FDA approval of the drugs a facility makes: compounded drugs are not FDA-approved.
Sources
- FDA. Facilities registered as human drug compounding outsourcing facilities under section 503B, updated November 17, 2026, with its notes on registration and inspections. fda.gov
- FDA. Registered outsourcing facilities: inspection status of ProRx LLC. fda.gov
- FDA. Drug recall enforcement reports for ProRx LLC, read through openFDA on November 20, 2026. open.fda.gov
Log every dose in mg with the vial it came from, so there is a record if something goes wrong.
Open Dose Insider